Medivation (MDVN) has become the pharmaceutical industry’s must-have biotech acquisition this year–Sanofi (SNY), AstraZeneca (AZN), Merck (MRK), and Pfizer (PFE) have been mentioned as potential acquirers. On Friday, however, Medivation made that a little more difficult by amending its bylaws to give its current board more leverage in negotiations. Citigroup’s Yigal Nochomovitz and Yang Huang explain:
